Peter Van Mourik

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Scedosporium infection as a late complication after start of elexacaftor/tezacaftor/ivacaftor: two case reports.

Scedosporium infection as a late complication after start of elexacaftor/tezacaftor/ivacaftor: two case reports.

Journal: Respiratory medicine case reports

Published: December 25, 2024

Repeatability and reproducibility of the Forskolin-induced swelling (FIS) assay on intestinal organoids from people with Cystic Fibrosis.

Repeatability and reproducibility of the Forskolin-induced swelling (FIS) assay on intestinal organoids from people with Cystic Fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: January 25, 2024

Centralized intestinal organoid generation is a feasible and safe approach for personalized medicine as demonstrated in the HIT-CF Europe Organoid Study.

Centralized intestinal organoid generation is a feasible and safe approach for personalized medicine as demonstrated in the HIT-CF Europe Organoid Study.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: January 12, 2024

FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes.

FDA-approved drug screening in patient-derived organoids demonstrates potential of drug repurposing for rare cystic fibrosis genotypes.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: September 13, 2022

Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis.

Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: June 15, 2022

Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators.

Prediction of Real-World Long-Term Outcomes of People with CF Homozygous for the F508del Mutation Treated with CFTR Modulators.

Journal: Journal of personalized medicine

Published: November 23, 2021

Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression.

Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression.

Journal: The European respiratory journal

Published: February 17, 2021

Protocol for Application, Standardization and Validation of the Forskolin-Induced Swelling Assay in Cystic Fibrosis Human Colon Organoids.

Protocol for Application, Standardization and Validation of the Forskolin-Induced Swelling Assay in Cystic Fibrosis Human Colon Organoids.

Journal: STAR protocols

Published: October 28, 2020

Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation.

Lumacaftor/ivacaftor in people with cystic fibrosis with an A455E-CFTR mutation.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: August 21, 2020

Comparison of Organoid Swelling and In Vivo Biomarkers of CFTR Function to Determine Effects of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation.

Comparison of Organoid Swelling and In Vivo Biomarkers of CFTR Function to Determine Effects of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for the F508del Mutation.

Journal: American journal of respiratory and critical care medicine

Published: July 21, 2020

R117H-CFTR function and response to VX-770 correlate with mRNA and protein expression in intestinal organoids.

R117H-CFTR function and response to VX-770 correlate with mRNA and protein expression in intestinal organoids.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: November 27, 2019

Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation.

Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: November 12, 2019

Showing 1-12 of 17

Last Updated: 09/26/2026